These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 34229001)
1. Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy. Yasaswi PS; Shetty K; Yadav KS J Control Release; 2021 Aug; 336():549-571. PubMed ID: 34229001 [TBL] [Abstract][Full Text] [Related]
2. Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers. Delello Di Filippo L; Hofstätter Azambuja J; Paes Dutra JA; Tavares Luiz M; Lobato Duarte J; Nicoleti LR; Olalla Saad ST; Chorilli M Eur J Pharm Biopharm; 2021 Nov; 168():76-89. PubMed ID: 34461214 [TBL] [Abstract][Full Text] [Related]
3. Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme. Jatyan R; Singh P; Sahel DK; Karthik YG; Mittal A; Chitkara D J Control Release; 2022 Oct; 350():494-513. PubMed ID: 35985493 [TBL] [Abstract][Full Text] [Related]
4. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma. Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821 [TBL] [Abstract][Full Text] [Related]
5. Temozolomide-fatty acid conjugates for glioblastoma multiforme: In vitro and in vivo evaluation. Jatyan R; Sahel DK; Singh P; Sakhuja R; Mittal A; Chitkara D J Control Release; 2023 Jul; 359():161-174. PubMed ID: 37182806 [TBL] [Abstract][Full Text] [Related]
6. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
7. Brain Targeting by Liposome-Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells. Arcella A; Palchetti S; Digiacomo L; Pozzi D; Capriotti AL; Frati L; Oliva MA; Tsaouli G; Rota R; Screpanti I; Mahmoudi M; Caracciolo G ACS Chem Neurosci; 2018 Dec; 9(12):3166-3174. PubMed ID: 30015470 [TBL] [Abstract][Full Text] [Related]
8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
9. Heme Oxygenase-1 targeting exosomes for temozolomide resistant glioblastoma synergistic therapy. Rehman FU; Liu Y; Yang Q; Yang H; Liu R; Zhang D; Muhammad P; Liu Y; Hanif S; Ismail M; Zheng M; Shi B J Control Release; 2022 May; 345():696-708. PubMed ID: 35341901 [TBL] [Abstract][Full Text] [Related]
10. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes. Jezierzański M; Nafalska N; Stopyra M; Furgoł T; Miciak M; Kabut J; Gisterek-Grocholska I Curr Oncol; 2024 Jul; 31(7):3994-4002. PubMed ID: 39057168 [TBL] [Abstract][Full Text] [Related]
11. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
12. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605 [TBL] [Abstract][Full Text] [Related]
13. Lumefantrine, an antimalarial drug, reverses radiation and temozolomide resistance in glioblastoma. Rajesh Y; Biswas A; Kumar U; Banerjee I; Das S; Maji S; Das SK; Emdad L; Cavenee WK; Mandal M; Fisher PB Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12324-12331. PubMed ID: 32409605 [TBL] [Abstract][Full Text] [Related]
14. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma. Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238 [TBL] [Abstract][Full Text] [Related]
15. Progress in research and development of temozolomide brain-targeted preparations: a review. Yang J; Xu Y; Fu Z; Chen J; Fan W; Wu X J Drug Target; 2023 Feb; 31(2):119-133. PubMed ID: 36039767 [TBL] [Abstract][Full Text] [Related]
16. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
17. Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair. Kim GW; Lee DH; Yeon SK; Jeon YH; Yoo J; Lee SW; Kwon SH Anticancer Res; 2019 Dec; 39(12):6731-6741. PubMed ID: 31810938 [TBL] [Abstract][Full Text] [Related]
18. The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. Wang S; Chen C; Li J; Xu X; Chen W; Li F J Neurol Sci; 2020 Jul; 414():116837. PubMed ID: 32334273 [TBL] [Abstract][Full Text] [Related]
19. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment. Iturrioz-Rodríguez N; Sampron N; Matheu A Theranostics; 2023; 13(9):2734-2756. PubMed ID: 37284445 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]